Marvin Reich,Matthew J. Simon,Beate Polke,Iñaki Paris,Georg Werner,Christian Schrader,Lena Spieth,Sonnet S. Davis,Sophie Robinson,Gabrielly Lunkes de Melo,Lennart Schlaphoff,Katrin Buschmann,Stefan Berghoff,Todd Logan,Brigitte Nuscher,Lis de Weerd,Dieter Edbauer,Mikael Simons,Jung H. Suh,Thomas Sandmann,Mihalis S. Kariolis,Sarah L. DeVos,Joseph W. Lewcock,Dominik Paquet,Anja Capell,Gilbert Di Paolo,Christian Haass

Abstract:Progranulin (PGRN) haploinsufficiency is a major risk factor for frontotemporal lobar degeneration with TAR DNA-binding protein 43 (TDP-43) pathology (FTLD- GRN ). Multiple therapeutic strategies are in clinical development to restore PGRN in the CNS, including gene therapy. However, a limitation of current gene therapy approaches aimed to alleviate FTLD-associated pathologies may be their inefficient brain exposure and biodistribution. We therefore developed an adeno-associated virus (AAV) targeting the liver (L) to achieve sustained peripheral expression of a transferrin receptor (TfR) binding, brain-penetrant (b) PGRN variant [AAV(L):bPGRN] in two mouse models of FTLD- GRN , namely, Grn knockout and GrnxTmem106b double knockout mice. This therapeutic strategy avoids potential safety and biodistribution issues of CNS-administered AAVs and maintains sustained concentrations of PGRN in the brain after a single dose. AAV(L):bPGRN treatment reduced several FTLD- GRN –associated pathologies including severe motor function deficits, aberrant TDP-43 phosphorylation, dysfunctional protein degradation, lipid metabolism, gliosis, and neurodegeneration in the brain. The potential translatability of our findings was tested in an in vitro model using cocultured human induced pluripotent stem cell (hiPSC)–derived microglia lacking PGRN and TMEM106B and wild-type hiPSC-derived neurons. As in mice, aberrant TDP-43, lysosomal dysfunction, and neuronal loss were ameliorated after treatment with exogenous TfR-binding protein transport vehicle fused to PGRN (PTV:PGRN). Together, our studies suggest that peripherally administered brain-penetrant PGRN replacement strategies ameliorate FTLD- GRN relevant phenotypes including TDP-43 pathology, neurodegeneration, and behavioral deficits. Our data provide preclinical proof of concept for the use of this AAV platform for treatment of FTLD- GRN and potentially other CNS disorders.

Establishment of A Stable Progranulin Deficient Cell Line: A Model of Frontotemporal Dementia with Ubiquitin-Positive Inclusions

An Alternative In Vitro Model Of Neurodegeneration In Ftld-U With Pgrn Mutation

Suppression of Progranulin Expression Leads to Formation of Intranuclear TDP-43 Inclusions in Vitro: A Cell Model of Frontotemporal Lobar Degeneration

Induced Pluripotent Stem Cell Models of Progranulin-Deficient Frontotemporal Dementia Uncover Specific Reversible Neuronal Defects.

Frontotemporal Dementia Patient Neurons With Progranulin Deficiency Display Protein Dyshomeostasis

Pathogenic cysteine mutations affect progranulin function and production of mature granulins.

Induced Pluripotent Stem Cell Models of Progranulin-Deficient Frontotemporal Dementia Uncover Specific Reversible Neuronal Defects

Progranulin promotes neurite outgrowth and neuronal differentiation by regulating GSK-3β

Establishment of Induced Pluripotent Stem Cell Line (Zzui009-A) from an Alzheimer's Disease Patient Carrying a PSEN1 Gene Mutation

RESEARCH ARTICLE Progranulin promotes neurite outgrowth and

Restoration of progranulin expression rescues cortical neuron generation in an induced pluripotent stem cell model of frontotemporal dementia

Progranulin Protects Against Amyloid Β Deposition and Toxicity in Alzheimer’s Disease Mouse Models

Progranulin as a therapeutic target in neurodegenerative diseases

Peripheral expression of brain-penetrant progranulin rescues pathologies in mouse models of frontotemporal lobar degeneration

Lysosomal functions of progranulin and implications for treatment of frontotemporal dementia

PGRN and frontotemporal lobar degeneration

Losing protein in the brain: the case of progranulin

Structure, Function, and Mechanism of Progranulin; the Brain and Beyond

Disease and Region Specificity of Granulin Immunopositivities in Alzheimer Disease and Frontotemporal Lobar Degeneration.

Elevated Progranulin Contributes to Synaptic and Learning Deficit Due to Loss of Fragile X Mental Retardation Protein.

Identification of biological pathways regulated by PGRN and GRN peptide treatments using transcriptome analysis